Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma.
Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma.
复制标题
DOI：
10.1007/s00404-018-4658-z
复制
发表时间：
2018-03
影响因子：
2.6
通讯作者：
Mikami M
中科院分区：
文献类型：
--
作者：
Matsuo K;Tanabe K;Ikeda M;Shibata T;Kajiwara H;Miyazawa M;Miyazawa M;Hayashi M;Shida M;Hirasawa T;Roman LD;Mikami M
完全唾液酸化的补体4结合蛋白α链（A2160）是糖蛋白家族的一员，最近已被确定为上皮性卵巢癌的诊断生物标志物。本研究考察了A2160作为该疾病预后生物标志物的实用性。这是一项回顾性分析，前瞻性收集了2009年至2014年期间接受初次细胞减灭术的93名I-IV期上皮性卵巢癌女性的血浆样本。治疗前A2160水平与临床病理因素和生存结局相关。与早期疾病患者相比，晚期疾病患者的2160水平显著更高（I-II期vs III-IV期，中位数2.17-2.70 vs 5.31-8.70 U/mL，P < 0.01）。与其他组织学类型相比，高级别浆液性卵巢癌患者的A2160水平更高（6.60 vs 3.01 U/mL，P = 0.05）。次优减灭组A2160水平显著高于优减/完全减灭组（7.02 vs 2.30-3.17 U/mL，P < 0.01）。在单变量分析中，较高的A2160水平与无进展生存率降低显著相关（64-100 vs. 1-33%ile，5年率53.4 vs. 78.9%，P = 0.029）。在控制年龄、CA-125水平、细胞减灭状态、组织学和分期后，较高的A2160水平仍然是无进展生存期降低的独立预后因素（调整风险比（HR）2.48，95%置信区间（CI）1.01-6.11，P = 0.049）。同样，多变量分析显示，较高的A2160水平与病因特异性生存率降低独立相关（调整后HR 3.07，95% CI 1.19-7.93，P = 0.021）。我们的研究表明，A2160可能是上皮性卵巢癌的一个有用的预后生物标志物，治疗前A2160水平越高，预后越差。
Fully sialylated alpha-chain of complement 4-binding protein (A2160) is a member of the glycoprotein family and has recently been identified as a diagnostic biomarker for epithelial ovarian cancer. This study examined the utility of A2160 as a prognostic biomarker for this disease. This is a retrospective analysis of prospectively collected plasma samples from 93 women with stage I–IV epithelial ovarian cancer who underwent primary cytoreductive surgery between 2009 and 2014. Pretreatment A2160 levels were correlated to clinico-pathological factors and survival outcome. Women with advanced-stage disease had significantly higher 2160 levels compared to those with early stage disease (stage I–II versus III–IV, median 2.17–2.70 versus 5.31–8.70 U/mL, P < 0.01). Women with high-grade serous ovarian carcinoma had higher A2160 levels compared to other histologies (6.60 versus 3.01 U/mL, P = 0.05). Women who had suboptimal cytoreduction had significantly higher A2160 levels than those who achieved optimal/complete cytoreduction (7.02 versus 2.30–3.17 U/mL, P < 0.01). On univariable analysis, higher A2160 levels were significantly associated with decreased progression-free survival (64–100 versus 1–33%ile, 5-year rates 53.4 versus 78.9%, P = 0.029). After controlling for age, CA-125 level, cytoreductive status, histology, and stage, higher A2160 levels remained an independent prognostic factor for decreased progression-free survival (adjusted-hazard ratio (HR) 2.48, 95% confidence interval (CI) 1.01–6.11, P = 0.049). Similarly, higher A2160 levels were independently associated with decreased cause-specific survival on multivariable analysis (adjusted-HR 3.07, 95% CI 1.19–7.93, P = 0.021). Our study suggests that A2160 may be a useful prognostic biomarker for epithelial ovarian cancer, and higher pretreatment levels of A2160 predicts poor survival outcome.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
4.7
作者：
Trudel, Dominique;Tetu, Bernard;Bairati, Isabelle
通讯作者：
Bairati, Isabelle
影响因子：
4.4
作者：
Holmberg, MT;Blom, AM;Meri, S
通讯作者：
Meri, S
影响因子：
4.7
作者：
Mikami M;Tanabe K;Matsuo K;Miyazaki Y;Miyazawa M;Hayashi M;Asai S;Ikeda M;Shida M;Hirasawa T;Kojima N;Sho R;Iijima S
通讯作者：
Iijima S
影响因子：
32.4
作者：
Brodeur, SR;Angelini, F;Geha, RS
通讯作者：
Geha, RS